Do analysts rate STVN or PSNL?

Personalis has a consensus price target of $14.54, suggesting a potential downside of 12.28%. Given Personalis' higher probable upside, analysts plainly believe Personalis is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stevanato Group 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.86 Personalis 1 Sell rating(s) 5 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.30

Which has stronger valuation & earnings, STVN or PSNL?

Stevanato Group has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Stevanato Group €1.34B 4.82 €158.21M €0.56 38.12 Personalis $69.65M 24.91 -$81.27M -$1.09 N/A

Does the media prefer STVN or PSNL?

In the previous week, Personalis had 12 more articles in the media than Stevanato Group. MarketBeat recorded 14 mentions for Personalis and 2 mentions for Stevanato Group. Personalis' average media sentiment score of 0.58 beat Stevanato Group's score of 0.00 indicating that Personalis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stevanato Group 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Personalis 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, PSNL or SHC?

Sotera Health has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Personalis $69.65M 24.91 -$81.27M -$1.09 N/A Sotera Health $1.16B 4.52 $77.94M $0.57 32.37

Is PSNL or SHC more profitable?

Sotera Health has a net margin of 13.44% compared to Personalis' net margin of -153.84%. Sotera Health's return on equity of 40.12% beat Personalis' return on equity. Company Net Margins Return on Equity Return on Assets Personalis -153.84% -46.47% -35.30% Sotera Health 13.44% 40.12% 7.55%

Does the media favor PSNL or SHC?

In the previous week, Personalis had 9 more articles in the media than Sotera Health. MarketBeat recorded 14 mentions for Personalis and 5 mentions for Sotera Health. Personalis' average media sentiment score of 0.58 beat Sotera Health's score of 0.46 indicating that Personalis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Personalis 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sotera Health 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ADPT or PSNL?

In the previous week, Adaptive Biotechnologies had 1 more articles in the media than Personalis. MarketBeat recorded 15 mentions for Adaptive Biotechnologies and 14 mentions for Personalis. Adaptive Biotechnologies' average media sentiment score of 0.59 beat Personalis' score of 0.58 indicating that Adaptive Biotechnologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Personalis 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ALMR or PSNL?

In the previous week, Personalis had 11 more articles in the media than Alamar Biosciences. MarketBeat recorded 14 mentions for Personalis and 3 mentions for Alamar Biosciences. Personalis' average media sentiment score of 0.58 beat Alamar Biosciences' score of 0.00 indicating that Personalis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alamar Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Personalis 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, PSNL or FTRE?

Personalis has higher earnings, but lower revenue than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Personalis $69.65M 24.91 -$81.27M -$1.09 N/A Fortrea $2.72B 0.70 -$986.20M -$0.91 N/A

Is PSNL or FTRE more profitable?

Fortrea has a net margin of -3.18% compared to Personalis' net margin of -153.84%. Fortrea's return on equity of 10.72% beat Personalis' return on equity. Company Net Margins Return on Equity Return on Assets Personalis -153.84% -46.47% -35.30% Fortrea -3.18% 10.72% 2.17%

Does the media favor PSNL or FTRE?

In the previous week, Personalis had 12 more articles in the media than Fortrea. MarketBeat recorded 14 mentions for Personalis and 2 mentions for Fortrea. Personalis' average media sentiment score of 0.58 beat Fortrea's score of 0.00 indicating that Personalis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Personalis 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fortrea 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Personalis (PSNL) Competitors

$16.57 +0.22 (+1.35%)

Closing price 04:00 PM Eastern

Extended Trading

$16.53 -0.04 (-0.24%)

As of 07:45 PM Eastern

Compare

PSNL vs. STVN, SHC, ADPT, ALMR, and FTRE

Should you buy Personalis stock or one of its competitors? Personalis's main competitors and comparable companies include Stevanato Group (STVN), Sotera Health (SHC), Adaptive Biotechnologies (ADPT), Alamar Biosciences (ALMR), and Fortrea (FTRE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Personalis compare to Stevanato Group?

Stevanato Group (NYSE:STVN) and Personalis (NASDAQ:PSNL) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

Stevanato Group has a net margin of 10.99% compared to Personalis' net margin of -153.84%. Stevanato Group's return on equity of 10.43% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stevanato Group	10.99%	10.43%	6.16%
Personalis	-153.84%	-46.47%	-35.30%

Personalis has a consensus price target of $14.54, suggesting a potential downside of 12.28%. Given Personalis' higher probable upside, analysts plainly believe Personalis is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stevanato Group	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.86
Personalis	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30

61.9% of Personalis shares are owned by institutional investors. 0.7% of Stevanato Group shares are owned by insiders. Comparatively, 4.2% of Personalis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Stevanato Group has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stevanato Group	€1.34B	4.82	€158.21M	€0.56	38.12
Personalis	$69.65M	24.91	-$81.27M	-$1.09	N/A

In the previous week, Personalis had 12 more articles in the media than Stevanato Group. MarketBeat recorded 14 mentions for Personalis and 2 mentions for Stevanato Group. Personalis' average media sentiment score of 0.58 beat Stevanato Group's score of 0.00 indicating that Personalis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stevanato Group	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Personalis	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Stevanato Group has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market. Comparatively, Personalis has a beta of 2.31, meaning that its stock price is 131% more volatile than the broader market.

Summary

Stevanato Group beats Personalis on 9 of the 17 factors compared between the two stocks.

How does Personalis compare to Sotera Health?

Personalis (NASDAQ:PSNL) and Sotera Health (NASDAQ:SHC) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

In the previous week, Personalis had 9 more articles in the media than Sotera Health. MarketBeat recorded 14 mentions for Personalis and 5 mentions for Sotera Health. Personalis' average media sentiment score of 0.58 beat Sotera Health's score of 0.46 indicating that Personalis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Personalis	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sotera Health	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

61.9% of Personalis shares are held by institutional investors. Comparatively, 91.0% of Sotera Health shares are held by institutional investors. 4.2% of Personalis shares are held by insiders. Comparatively, 15.4% of Sotera Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Personalis has a beta of 2.31, meaning that its share price is 131% more volatile than the broader market. Comparatively, Sotera Health has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

Sotera Health has a net margin of 13.44% compared to Personalis' net margin of -153.84%. Sotera Health's return on equity of 40.12% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Personalis	-153.84%	-46.47%	-35.30%
Sotera Health	13.44%	40.12%	7.55%

Personalis presently has a consensus target price of $14.54, suggesting a potential downside of 12.28%. Sotera Health has a consensus target price of $21.50, suggesting a potential upside of 16.53%. Given Sotera Health's stronger consensus rating and higher probable upside, analysts plainly believe Sotera Health is more favorable than Personalis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Personalis	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30
Sotera Health	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Sotera Health has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Personalis	$69.65M	24.91	-$81.27M	-$1.09	N/A
Sotera Health	$1.16B	4.52	$77.94M	$0.57	32.37

Summary

Sotera Health beats Personalis on 12 of the 16 factors compared between the two stocks.

How does Personalis compare to Adaptive Biotechnologies?

Adaptive Biotechnologies (NASDAQ:ADPT) and Personalis (NASDAQ:PSNL) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

In the previous week, Adaptive Biotechnologies had 1 more articles in the media than Personalis. MarketBeat recorded 15 mentions for Adaptive Biotechnologies and 14 mentions for Personalis. Adaptive Biotechnologies' average media sentiment score of 0.59 beat Personalis' score of 0.58 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Personalis	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 61.9% of Personalis shares are held by institutional investors. 5.7% of Adaptive Biotechnologies shares are held by insiders. Comparatively, 4.2% of Personalis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Adaptive Biotechnologies has higher revenue and earnings than Personalis. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$276.98M	17.04	-$59.50M	-$0.41	N/A
Personalis	$69.65M	24.91	-$81.27M	-$1.09	N/A

Adaptive Biotechnologies has a beta of 2.09, meaning that its stock price is 109% more volatile than the broader market. Comparatively, Personalis has a beta of 2.31, meaning that its stock price is 131% more volatile than the broader market.

Adaptive Biotechnologies currently has a consensus target price of $27.07, indicating a potential downside of 8.45%. Personalis has a consensus target price of $14.54, indicating a potential downside of 12.28%. Given Adaptive Biotechnologies' stronger consensus rating and higher possible upside, research analysts plainly believe Adaptive Biotechnologies is more favorable than Personalis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Personalis	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30

Adaptive Biotechnologies has a net margin of -20.73% compared to Personalis' net margin of -153.84%. Adaptive Biotechnologies' return on equity of -36.81% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%
Personalis	-153.84%	-46.47%	-35.30%

Summary

Adaptive Biotechnologies beats Personalis on 13 of the 16 factors compared between the two stocks.

How does Personalis compare to Alamar Biosciences?

Alamar Biosciences (NASDAQ:ALMR) and Personalis (NASDAQ:PSNL) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

Alamar Biosciences has a net margin of 0.00% compared to Personalis' net margin of -153.84%. Alamar Biosciences' return on equity of 0.00% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alamar Biosciences	N/A	N/A	N/A
Personalis	-153.84%	-46.47%	-35.30%

In the previous week, Personalis had 11 more articles in the media than Alamar Biosciences. MarketBeat recorded 14 mentions for Personalis and 3 mentions for Alamar Biosciences. Personalis' average media sentiment score of 0.58 beat Alamar Biosciences' score of 0.00 indicating that Personalis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alamar Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Personalis	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.9% of Personalis shares are held by institutional investors. 4.2% of Personalis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Alamar Biosciences presently has a consensus price target of $31.80, indicating a potential downside of 4.22%. Personalis has a consensus price target of $14.54, indicating a potential downside of 12.28%. Given Alamar Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Alamar Biosciences is more favorable than Personalis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alamar Biosciences	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Personalis	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30

Alamar Biosciences has higher revenue and earnings than Personalis. Alamar Biosciences is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alamar Biosciences	$74.21M	31.04	-$29.82M	-$1.96	N/A
Personalis	$69.65M	24.91	-$81.27M	-$1.09	N/A

Summary

Alamar Biosciences beats Personalis on 8 of the 14 factors compared between the two stocks.

How does Personalis compare to Fortrea?

Personalis (NASDAQ:PSNL) and Fortrea (NASDAQ:FTRE) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

Personalis has higher earnings, but lower revenue than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Personalis	$69.65M	24.91	-$81.27M	-$1.09	N/A
Fortrea	$2.72B	0.70	-$986.20M	-$0.91	N/A

61.9% of Personalis shares are owned by institutional investors. 4.2% of Personalis shares are owned by insiders. Comparatively, 0.7% of Fortrea shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Personalis currently has a consensus price target of $14.54, indicating a potential downside of 12.28%. Fortrea has a consensus price target of $22.00, indicating a potential upside of 9.89%. Given Fortrea's stronger consensus rating and higher probable upside, analysts plainly believe Fortrea is more favorable than Personalis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Personalis	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30
Fortrea	1 Sell rating(s)	5 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36

Fortrea has a net margin of -3.18% compared to Personalis' net margin of -153.84%. Fortrea's return on equity of 10.72% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Personalis	-153.84%	-46.47%	-35.30%
Fortrea	-3.18%	10.72%	2.17%

In the previous week, Personalis had 12 more articles in the media than Fortrea. MarketBeat recorded 14 mentions for Personalis and 2 mentions for Fortrea. Personalis' average media sentiment score of 0.58 beat Fortrea's score of 0.00 indicating that Personalis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Personalis	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fortrea	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Personalis has a beta of 2.31, indicating that its share price is 131% more volatile than the broader market. Comparatively, Fortrea has a beta of 1.97, indicating that its share price is 97% more volatile than the broader market.

Summary

Personalis and Fortrea tied by winning 8 of the 16 factors compared between the two stocks.

Get Personalis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PSNL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PSNL vs. The Competition

Export

Metric	Personalis	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.71B	$10.52B	$7.33B	$13.29B
Dividend Yield	N/A	1.45%	2.52%	12.57%
P/E Ratio	-15.20	60.82	214.34	21.27
Price / Sales	24.91	109.39	639.66	87.10
Price / Cash	N/A	27.90	77.80	52.76
Price / Book	5.64	6.06	10.52	6.34
Net Income	-$81.27M	$56.67B	$3.49B	$360.00M
7 Day Performance	2.09%	3.74%	-1.08%	-0.11%
1 Month Performance	-2.87%	4.13%	-3.39%	-3.42%
1 Year Performance	173.43%	37.40%	15.08%	5.46%

Personalis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PSNL Personalis	2.0076 of 5 stars	$16.57 +1.3%	$14.54 -12.3%	+167.6%	$1.71B	$69.65M	N/A	260	News Coverage Insider Trade
STVN Stevanato Group	2.1022 of 5 stars	€21.50 0.0%	N/A	-19.6%	€6.51B	€1.34B	38.39	6,010
SHC Sotera Health	3.5555 of 5 stars	$18.70 -0.2%	$21.50 +15.0%	+14.3%	$5.35B	$1.16B	32.81	3,000
ADPT Adaptive Biotechnologies	1.7159 of 5 stars	$27.86 -2.6%	$24.42 -12.4%	+100.2%	$4.57B	$276.98M	N/A	624	Analyst Forecast
ALMR Alamar Biosciences	1.1844 of 5 stars	$35.05 +0.6%	$31.80 -9.3%	N/A	$2.42B	$74.21M	N/A	222	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PSNL) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Personalis (PSNL) Competitors

PSNL vs. STVN, SHC, ADPT, ALMR, and FTRE

How does Personalis compare to Stevanato Group?

Summary

How does Personalis compare to Sotera Health?

Summary

How does Personalis compare to Adaptive Biotechnologies?

Summary

How does Personalis compare to Alamar Biosciences?

Summary

How does Personalis compare to Fortrea?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSNL vs. The Competition

Personalis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Personalis (PSNL) Competitors

PSNL vs. STVN, SHC, ADPT, ALMR, and FTRE

How does Personalis compare to Stevanato Group?

Is STVN or PSNL more profitable?

Do analysts rate STVN or PSNL?

Do insiders & institutionals have more ownership in STVN or PSNL?

Which has stronger valuation & earnings, STVN or PSNL?

Does the media prefer STVN or PSNL?

Which has more risk & volatility, STVN or PSNL?

Summary

How does Personalis compare to Sotera Health?

Does the media favor PSNL or SHC?

Do insiders & institutionals have more ownership in PSNL or SHC?

Which has more risk and volatility, PSNL or SHC?

Is PSNL or SHC more profitable?

Do analysts recommend PSNL or SHC?

Which has higher earnings and valuation, PSNL or SHC?

Summary

How does Personalis compare to Adaptive Biotechnologies?

Does the media refer more to ADPT or PSNL?

Do institutionals and insiders have more ownership in ADPT or PSNL?

Which has preferable valuation and earnings, ADPT or PSNL?

Which has more volatility & risk, ADPT or PSNL?

Do analysts rate ADPT or PSNL?

Is ADPT or PSNL more profitable?

Summary

How does Personalis compare to Alamar Biosciences?

Is ALMR or PSNL more profitable?

Does the media refer more to ALMR or PSNL?

Do insiders and institutionals have more ownership in ALMR or PSNL?

Do analysts rate ALMR or PSNL?

Which has higher earnings and valuation, ALMR or PSNL?

Summary

How does Personalis compare to Fortrea?

Which has stronger earnings & valuation, PSNL or FTRE?

Do institutionals and insiders have more ownership in PSNL or FTRE?

Do analysts recommend PSNL or FTRE?

Is PSNL or FTRE more profitable?

Does the media favor PSNL or FTRE?

Which has more risk & volatility, PSNL or FTRE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSNL vs. The Competition

Personalis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools